{"organizations": [], "uuid": "034fe03a6da65bd08103e3906b36d7427e6d076d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-takeda-and-denali-therapeutics-col/brief-takeda-and-denali-therapeutics-collaborate-to-develop-therapies-for-neurodegenerative-diseases-idUSFWN1P00D7", "country": "US", "domain_rank": 408, "title": "BRIEF-Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T14:14:00.000+02:00", "replies_count": 0, "uuid": "034fe03a6da65bd08103e3906b36d7427e6d076d"}, "author": "", "url": "https://www.reuters.com/article/brief-takeda-and-denali-therapeutics-col/brief-takeda-and-denali-therapeutics-collaborate-to-develop-therapies-for-neurodegenerative-diseases-idUSFWN1P00D7", "ord_in_thread": 0, "title": "BRIEF-Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "denali therapeutics", "sentiment": "none"}, {"name": "takeda pharmaceutical co ltd", "sentiment": "none"}, {"name": "takeda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 15 PM / in 6 minutes BRIEF-Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases Reuters Staff \nJan 5 (Reuters) - Takeda Pharmaceutical Co Ltd: \n* TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES \n* DENALI THERAPEUTICS - TAKEDA TO MAKE AN INITIAL PAYMENT TO CO OF $150 MILLION THROUGH COMBINATION OF CASH UPFRONT PAYMENTS AND PURCHASE OF DENALI EQUITY \n* DENALI THERAPEUTICS - TO BE RESPONSIBLE FOR DEVELOPMENT ACTIVITIES AND COSTS PRIOR TO IND FILING FOR EACH OF THREE PROGRAMS \n* DENALI - WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS, INCLUDING $90 MILLION IN PRECLINICAL MILESTONES & OPT-IN PAYMENTS \n* DENALI THERAPEUTICS - COLLABORATION AGREEMENT TO DEVELOP,COMMERCIALIZE UP TO 3 SPECIFIED THERAPEUTIC PRODUCT CANDIDATES FOR NEURODEGENERATIVE DISEASES \n* DENALI - TAKEDA, CO WILL JOINTLY COMMERCIALIZE PRODUCTS IN U.S., CHINA, TAKEDA WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS IN ALL OTHER MARKETS \n* DENALI THERAPEUTICS - TAKEDA, CO WILL SHARE GLOBAL PROFITS FROM COLLABORATION EQUALLY \n* DENALI THERAPEUTICS INC - TAKEDA HAS OPTION TO CO-DEVELOP AND CO-COMMERCIALIZE EACH OF THREE PROGRAMS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T14:14:00.000+02:00", "crawled": "2018-01-05T14:32:31.077+02:00", "highlightTitle": ""}